0 Replies
Download PDF
Santaris Pharma A/S selects lead research compound SPC5001 targeting PCSK9 to advance into drug development for the treatment of high cholesterol
PCSK9, an important new target, is a protein involved in regulating LDL or “bad” cholesterol in the blood– a major risk factor for coronary heart disease,... Contine Reading & Discuss→
0 Replies
BOULDER, Colo., April 23, 2010 – miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that its Chief Scientific Advisor and Co-Founder, Eric N. Olson, Ph.D., will give a plenary lecture at the joint meeting... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Apr 23, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development... Contine Reading & Discuss→
0 Replies
Stories include:
FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 90,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!
About... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Apr 19, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Anastasia Khvorova, Ph.D., Chief Scientific Officer, is presenting at the 101st annual American Association for Cancer Research (AACR) Conference... Contine Reading & Discuss→
